Rapid Cancer Tests Market 2020 Precise Outlook – Abingdon Health, Hologic, Abbott, NanoEntek, Biomerica, Alfa Scientific Designs, Exact Sciences, Biosynex

The Rapid Cancer Tests Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Click the link to get a Sample Copy of the Report:
https://www.marketinsightsreports.com/reports/03311940937/global-rapid-cancer-tests-market-growth-2020-2025/inquiry?source=openpr&Mode=12

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Rapid Cancer Tests Market: Abingdon Health, Hologic, Abbott, NanoEntek, Biomerica, Alfa Scientific Designs, Exact Sciences, Biosynex, Firstep Bioresearch, IDL Biotech, LifeAssays and others.

Industry News:

Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening

10/27/2020: MADISON, Wis. and CAMBRIDGE, Mass -- Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion. The transaction was unanimously approved by both companies' Boards of Directors and is anticipated to close during the first quarter of 2021, subject to regulatory approval and the satisfaction of other conditions.

Combining Thrive's pioneering early-stage screening test, CancerSEEK, with Exact Sciences' best-in-class scientific platform, clinical organization, and commercial infrastructure will establish Exact Sciences as a leading competitor in blood-based, multi-cancer screening. Thrive, with an early version of CancerSEEK, has conducted a first-of-its-kind 10,000-patient, prospective, interventional study in a real-world clinical setting. In this landmark study, using its mutation and protein biomarker approach, CancerSEEK achieved promising results detecting 10 different types of cancer, including seven with no recommended screening guidelines, with very few false positives. Bringing together highly complementary scientific approaches and the strengths of both organizations, Exact Sciences expects to develop a more accurate test and accelerate the widespread adoption of this potentially life-saving advancement.

Abbott Gets FDA Nod for Rapid Point-of-Care COVID-19 Antigen Test

OCT.1.2020: The Food and Drug Administration (FDA) has issued an emergency use authorization for Abbott’s BinaxNow COVID-19 Ag Card, the first antigen test that displays results on a testing card similar to an over-the-counter pregnancy test. To perform this test, a healthcare provider first swabs a patient’s nose and mixes the collected sample with a reagent on the test card. After 15 minutes, the result appears on the card, with one line indicating a negative result and two lines indicating a positive result. The BinaxNow COVID-19 Ag Card is authorized for use within 7 days of symptom onset in patients whose healthcare providers suspect they have COVID-19. In FDA’s announcement of its authorization for this test, the agency also notes that, in general, antigen tests have high specificity, but are not as sensitive as molecular tests. Due to this potential for decreased sensitivity, providers and labs might need to confirm negative results from Abbott’s test with a molecular test prior to making treatment decisions.

Guardant Health has received Food and Drug Administration (FDA) approval for the Guardant360 CDx assay, making this the first FDA-approved liquid biopsy companion diagnostic that uses next-generation sequencing technology. Intended for use in non-small cell lung cancer (NSCLC) patients, the test simultaneously detects mutations in 55 tumor genes, with a particular focus on mutations of the epidermal growth factor receptor gene that indicate whether a patient might benefit from treatment with Tagrisso (osimertinib). Tagrisso is an FDA-approved therapy developed by AstraZeneca for metastatic NSCLC. The Guardant360 CDx is also approved to provide information on multiple other solid tumor biomarkers, but genomic findings for these other biomarkers are not currently validated for choosing a particular corresponding treatment. Additionally, labs should be aware that if the Guardant360 Dx does not detect the specific NSCLC mutations associated with this FDA approval, then a follow-up tumor biopsy should be performed to confirm whether or not these mutations are present.

Global Rapid Cancer Tests Market Split by Product Type and Applications:

This report segments the market on the basis of Types are:

Blood Test
Urine Test
Others

On the basis of Application, the market is segmented into:

Hospitals
Clinics
Others

Buy The Report:

https://www.marketinsightsreports.com/report/purchase/03311940937?mode=su?source=openpr&Mode=12

Regional Analysis For Rapid Cancer Tests Market:
For comprehensive understanding of market dynamics, the global Rapid Cancer Tests market is analyzed across key geographies namely:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Rapid Cancer Tests Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger and acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2020–2025.

Following are major Table of Content of Rapid Cancer Tests Market:

- Global Market Overview, Drivers, Restraints and Opportunities, Segmentation overview
- Global Market competition by top Players
- Analysis by Regions
- Consumption by Regions
- Consumption, By Types, Revenue and Market share by Types
- Consumption, By Applications, Market share (%) and Growth Rate by Applications
- Complete profiling and analysis of Players
- Industrial Chain, Sourcing Strategy and Downstream Buyers
- Marketing Strategy Analysis, Distributors/Traders
- Global Market Effect Factors Analysis
- Global Market Forecast
- Global Market Research Findings and Conclusion, Appendix, methodology and data source

Finally, all aspects of the Global Market are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects. The report supplies the international economic competition with the assistance of Porter’s Five Forces Analysis and SWOT Analysis.

For More Information On This Report, Please Visit:
https://www.marketinsightsreports.com/reports/03311940937/global-rapid-cancer-tests-market-growth-2020-2025?source=openpr&Mode=12

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.
Please connect with our sales team (sales@marketinsightsreports.com).

Browse Related Reports:

Precision Cancer Tests Market:
https://www.marketinsightsreports.com/reports/06032064860/covid-19-impact-on-global-precision-cancer-tests-market-size-status-and-forecast-2020-2026?source=openpr&Mode=12

Rapid Point-of-Care (PoC) Diagnostics Market:
https://www.marketinsightsreports.com/reports/11022413967/global-rapid-point-of-care-poc-diagnostics-market-growth-status-and-outlook-2019-2024?source=openpr&Mode=12

Rapid Virus Diagnostic Test Market:
https://www.marketinsightsreports.com/reports/11022412322/global-rapid-virus-diagnostic-test-market-size-status-and-forecast-2020-2026?source=openpr&Mode=12

Note: All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

CONTACT US:
Irfan Tamboli (Head of Sales) - Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

ABOUT US:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.